Pharma · Private company
Janssen Biotech, Inc.
Track this companyFree. Adds Janssen Biotech, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials134 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- abiraterone acetate in combination with prednisonePhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Anti TNF therapy including infliximabCrohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibRelapsed or Refractory Mantle Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- No BiologicsCrohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- Daratumumab in HLA Desensitization Prior to TransplantationPHASE2 · ENROLLING_BY_INVITATION · started Mar 31, 2022ClinicalTrials.gov NCT05300451 · fetched Nov 12, 2026
- Guselkumab ImmunogeneticsPHASE4 · COMPLETED · started Mar 1, 2021ClinicalTrials.gov NCT04645355 · fetched Nov 12, 2026
- A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian SubjectsPHASE1 · COMPLETED · started Jul 17, 2018ClinicalTrials.gov NCT03586570 · fetched Nov 12, 2026
- A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its SafetyPHASE3 · COMPLETED · started Jun 18, 2018ClinicalTrials.gov NCT03541174 · fetched Nov 12, 2026
- A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadPHASE1_PHASE2 · COMPLETED · started Jun 15, 2017ClinicalTrials.gov NCT03098550 · fetched Nov 12, 2026
- An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisACTIVE_NOT_RECRUITING · started Dec 16, 2016ClinicalTrials.gov NCT02808780 · fetched Nov 12, 2026
- Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaPHASE1 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02309580 · fetched Nov 12, 2026
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)PHASE1_PHASE2 · COMPLETED · started Dec 8, 2014ClinicalTrials.gov NCT02315326 · fetched Nov 12, 2026
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRECRUITING · started Nov 1, 2013ClinicalTrials.gov NCT02103361 · fetched Nov 12, 2026
- A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyPHASE2 · COMPLETED · started Sep 26, 2012ClinicalTrials.gov NCT01711814 · fetched Nov 12, 2026
- IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenPHASE2 · COMPLETED · started May 4, 2011ClinicalTrials.gov NCT01314118 · fetched Nov 12, 2026
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseACTIVE_NOT_RECRUITING · started May 31, 2007ClinicalTrials.gov NCT00606346 · fetched Nov 12, 2026
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT01833039 · fetched Nov 12, 2026